The Office of Biotechnology Transfer (OBT) was created in 1995 within Science Park Raf SpA (SPR), with the aim of managing all the Science Park's technology transfer activities related to biotechnology, such as:
- technology innovation and transfer
-
licencing in/out
-
patent policy
-
creation of biotechnology start-up companies and joint-ventures
-
definition of research and development contracts and project management
-
promotion of biotechnology transfer from basic research to private companies or directly to the market
-
assistance in the marketing and commercialisation of products and activities generated by the various research projects in the Science Park

Staff

Head of Biotechnology Transfer: Giorgio Chieregatti - General Manager - SPR
Assistant: Ilaria Castellazzi
Associate Biotechnology Transfer: Daniela Bellomo
Associate Biotechnology Transfer: Lucia Faccio
Technical Services: Marco Crespi
Informatic Support: Sonia Fiorentini

Biotechnology Transfer Office Activities
(1995 - 2001)


In this page
Staff
Biotechnology Transfer Office Activities
(1995 - 2001)

Some basic on Patents
Protecting your ability to get a patent
Patent process
Technology Development and Licensing
Patents available for licensing
Links of Tech Transfer Interest

Report of Invention Form
Material Transfer Agreement, MTA
Animal Transfer Agreement, ATA
Filed patent applications 44
R&D contracts 157
Companies involved in R&D contracts 59
Spin-off companies 3
Companies and other initiatives in the park 10


Some basic on Patents

A patent for an invention is a contract between the inventor or the company sponsoring the inventor and the state, that allows the inventor to stop others from commercially benefiting from the invention for a limited time in a specific country or area.
A patent provides a 20 years' protection against unauthorised use or copying of the invention, and increases the likelihood of commercial investment in technology.

An invention to be patented has to meet three basic requirements:

  • Novelty: the invention cannot be patented if it is already known to the public
  • Inventiveness: the invention cannot be obvious
  • Industrial applicability: the invention needs to have a potential market

What is patentable?

  • Biological material like: viruses, microorganisms, proteins, DNA sequences whose function is known, etc
  • Transgenic animals with specific genetic features that can be used to produce new drugs to treat for example, diabetes, cancer, multiple sclerosis etc
  • Transgenic plants with improved qualities that affect their nutritional properties or their resistance to insects and diseases
  • Plants and animal varieties are not patentable because they are the result of biological (natural) methods of production

There are certain things that are deemed to be unpatentable

  • A discovery, scientific theory or mathematical method
  • A literary, dramatic, musical or artistic work or any aesthetic work whatsoever
  • A scheme, rule or method for performing a mental act, playing a game or doing a business, or a program for a computer (software)
  • The presentation of information
  • Methods for surgical or therapeutic treatment of the human and animal body
  • Diagnostic methods applicable to humans and animals

Protecting your ability to get a patent

Remember

  • Any written or oral "prior disclosure" to any member of the general public (those outside the San Raffaele Biomedical Science Park community), can invalidate a patent

Before you disclose any new aspects of your work

  • Think about possible commercial developments
  • Contact us if you think your work has potential commercial interest
  • A patent application can be filed very quickly when necessary, and can significantly enhance the chances that a technology will be developed and generate further research funds for you
  • It is hardly ever necessary to delay a publication/ talk/research poster in order to protect the technology it describes with a patent
  • If an inadvertent disclosure is made, patent protection in the US is still possible if filing is made within 12 months

Patent process

It is not always straightforward to judge whether an invention is patentable, so scientists should contact us as early as possible by filing a Report of Invention Form to the Office of Biotechnology Transfer (OBT). The OBT will give a first evaluation on the patentability of the invention in terms of contents, prior art and potential market, then a Grant and Intellectual Property Committee composed of the scientific board and internal and external consultants will take the final decision on whether to file a patent.
If a decision is made not to file a patent then the San Raffaele Foundation will reassign the rights on the intellectual property to the inventor.
Do you have a new invention that you want to report to Science Park Raf?
Then fill in the Report of Invention Form

Technology Development and Licensing

Science Park Raf is pro-active in identifying research with commercial potential and in marketing new technologies to industry. For this purpose it is very important to protect our Intellectual Property with Transfer Agreements (Material Transfer Agreement, MTA and Animal Transfer Agreement, ATA) whenever there is a transfer of technology or biological material to third parties.

MTAs are contracts which rule the transfer of material that is not commercially available from the owner or licenser towards an external institution for research purposes only.
MTAs define questions regarding the property of the material transferred and of the modifications and developments done on it by the receiver, the secrecy on the material's feature and the rights on inventions and results developed from those materials.
Everytime a scientist working at San Raffaele needs to transfer material to another institution profit or non-profit or to obtain material from another institution a MTA agreement needs to be signed before any material is transferred.

One of the Science Park Raf principal activities is the negotiation of licenses for technologies developed within the San Raffaele Biomedical Science Park.
A license agreement is required when a company wants to acquire the right to use or commercialise either an unpatented material or a patented one or a patent pending invention developed in the San Raffaele Biomedical Science Park. A license is a legal agreement by which the owner of the intellectual property grants the licensee the right to use and commercialise eventually after further development the invention. The agreement defines also the commercial value of the licensed material and eventual rights of the licenser on the revenues derived from the commercialisation of the product. Science Park Raf plays an important role in assessing a value to the property and in the negotiation of the best ways to support San Raffaele research in order to develop product of use and value for the community.

If you are a company seeking to license an invention these patents are available for licensing:

1. Modified cytokines for therapeutic use
Application PCT/EP97/00704
Priority 27.02.96
Inventors Corti A et al

2. Method for the production of activated marker tumor-specific T-cells and use thereof in treatment of tumors
Application WO97/37004
Priority 30.03.96
Inventors Dellabona P,
Casorati G

3. uPA-R mimicking peptide
Application WO98/42733
Priority 20.03.97
Inventors Blasi F et al

4. Method for nucleic acid detection by Real Time PCR
Application PCT/EP99/08847
Priority 17.11.98
Inventors Malnati M, Lusso P et al

5. MAGE-3 derived immunogenic peptides presented by MHC of Class II and the use thereof
Application PCT/EPO0/ 01458
Priority 26.02.99
Inventors Protti P, Dellabona P

6. RANTES peptides with anti-HIV activity
Application WO 00/27880
Priority 11.11.1998
Inventors Lusso P, Pavone V

7. Anti-HIV action of pro-Urokinase, identification of the transmembrane mediator of pro-urokinase and urokinase receptor in chemotaxis, a method to identify and quantify specific activated fragments of u-PAR
Application PCT/EP02/00603
Priority 25.01.2001
Inventors Blasi F et al

8. CCR5 specific human recombinant monoclonal antibodies down modulate surface CCR5 and protect from HIV-1 infection
Application US 805,375
Priority 14.03.2001
Inventors Lopalco L

9. Human CD25+, CD4+ T cells with regulatory/suppressive activity
Application US 60/294,030
Priority 30.05.2001
Inventors Roncarolo MG,
Levings M

10. Agents that protects vessels from vascular leakage
Application MI2001A001833
Priority 30.08.2001
Inventors Corti A, Ferrero E

11. Method and compositions for the activation of dendritic cells
Application MI2001A001986
Priority 25.09.2001
Inventors Bianchi M, Manfredi A

Links of Tech Transfer Interest
Assn. of University Technology Managers
Global technoscan
PharmaLicensing
TechEx

Links for Patents Searches
Delphion Intellectual Property Network
DialogWeb
European Patent Office (EPO)
PIPERS Virtual Intellectual Property Library
USPTO Web Patent Databases

Links for Intellectual Property
IP Links
World Intellectual Property Organization

Biotechnology Related Links
4Biotech.com
Bio
BioMedNet
BioSpace
Genetic Engineering News
Institute for Biotechnology Information

Venture Capital Links
A.I.F.I.
Bioportfolio

Recombinant Capital
SIFT Network - Professional Venture Capital Sources
The Venture Capital Journal

Office of Biotechnology Transfer
via Olgettina, 58 - 20132 Milano (Italy)
phone +39 02 26434882
fax +39 02 26434881
Contact person